Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab and Blinatumomab in Adult B-ALL
NCT07313852Phase 2Not yet recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin, blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicinblinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07313852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313852.